"Cardiovascular safety concerns have significantly impacted prescriptions for Avandia and created opportunities for other antidiabetic agents," said Donny Wong, Ph.D., principal analyst at Decision Resources. "Nearly three-quarters of physicians say they have switched patients to Januvia as a result of the Avandia meta-analysis, and one-third of PCPs and endocrinologists say they have switched patients to Byetta following publication of the Avandia meta-analysis. Nevertheless, Takeda's Actos will continue to be the market share leader among oral antidiabetic agents until the drug loses patent protection in 2011."
Avandia One Year Later-A Physician and Payer Perspective is based on a U.S. survey of 74 PCPs, 70 endocrinologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.
About Physician & Payer Forum
Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.
About Decision Resources
Decision Resources (http://www.DecisionResources.com) is a world leader
in market research publications, advisory services, and consulting designed
to help clients shape strategy, allocate resources, and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
|SOURCE Decision Resources|
Copyright©2008 PR Newswire.
All rights reserved